Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Cholangiocarcinoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Mouth Neoplasms 1Metastatic NUT Carcinoma 1Laryngeal Neoplasms 1Klatskin Tumor 1Infiltrating Bladder Urothelial Carcinoma 1Hypopharyngeal Neoplasms 1HIV Infections 1Carcinoma 1Borderline Resectable Pancreatic Adenocarcinoma 1Bile Duct Neoplasms 1

Interventions

transplatin 1pembrolizumab 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Gemcitabine 1Cystectomy 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Infiltrating Bladder Urothelial Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Mayo Clinic

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡